Evolent Health, Inc. (EVH)
NYSE: EVH · IEX Real-Time Price · USD
27.65
-0.67 (-2.37%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Evolent Health Revenue
In the year 2023, Evolent Health had annual revenue of $1.96B with 45.26% growth. Revenue in the quarter ending December 31, 2023 was $556.06M with 45.40% year-over-year growth.
Revenue (ttm)
$1.96B
Revenue Growth
+45.26%
P/S Ratio
1.63
Revenue / Employee
$417,850
Employees
4,700
Market Cap
3.19B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.96B | 611.88M | 45.26% |
Dec 31, 2022 | 1.35B | 444.06M | 48.91% |
Dec 31, 2021 | 907.96M | -16.68M | -1.80% |
Dec 31, 2020 | 924.64M | 237.52M | 34.57% |
Dec 31, 2019 | 687.12M | 60.06M | 9.58% |
Dec 31, 2018 | 627.06M | 192.11M | 44.17% |
Dec 31, 2017 | 434.95M | 180.76M | 71.11% |
Dec 31, 2016 | 254.19M | 157.31M | 162.38% |
Dec 31, 2015 | 96.88M | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 25.67M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortrea Holdings | 3.11B |
Envista Holdings | 2.57B |
Sotera Health Company | 1.05B |
HUTCHMED (China) | 838.00M |
10x Genomics | 618.73M |
Axonics | 366.38M |
Axsome Therapeutics | 270.60M |
SpringWorks Therapeutics | 5.45M |
EVH News
- 9 days ago - Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 - PRNewsWire
- 2 months ago - Evolent Announces Fourth Quarter and Full Year 2023 Results - PRNewsWire
- 2 months ago - Evolent Adds Russell Glass, Headspace CEO, to Board of Directors - PRNewsWire
- 3 months ago - Evolent to Release Fourth Quarter 2023 Financial Results on Thursday, February 22, 2024 - PRNewsWire
- 5 months ago - Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan - PRNewsWire
- 5 months ago - Evolent Health, Inc. Announces Proposed Offering of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan - PRNewsWire
- 6 months ago - Evolent Announces Third Quarter 2023 Results - PRNewsWire
- 7 months ago - Evolent to release third quarter financial results on Thursday, Nov. 2, 2023, and participate in upcoming investor conferences - PRNewsWire